Douglas Lane & Associates, LLC Abb Vie Inc. Transaction History

Douglas Lane & Associates, LLC

$7.1 Billion
Q3 2024

A detailed history of Douglas Lane & Associates, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Douglas Lane & Associates, LLC holds 10,621 shares of ABBV stock, worth $1.86 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

10,621

Previous 11,096 4.28%

Holding current value

$1.86 Million

Previous $1.9 Million 10.19%

% of portfolio

0.03%

Previous 0.03%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$163.84 - $199.33 $77,824 - $94,681	-475 Reduced 4.28%	10,621 $2.1 Million
Q2 2024 Jul 08, 2024	SELL	$154.79 - $180.76 $79,716 - $93,091	-515 Reduced 4.44%	11,096 $1.9 Million
Q1 2024 Apr 11, 2024	SELL	$159.82 - $182.1 $59,612 - $67,923	-373 Reduced 3.11%	11,611 $2.11 Million
Q4 2023 Jan 17, 2024	SELL	$137.6 - $154.97 $194,291 - $218,817	-1,412 Reduced 10.54%	11,984 $1.86 Million
Q3 2023 Oct 16, 2023	BUY	$133.59 - $154.65 $130,784 - $151,402	979 Added 7.88%	13,396 $2 Million
Q2 2023 Jul 19, 2023	BUY	$132.51 - $164.9 $34,717 - $43,203	262 Added 2.16%	12,417 $1.67 Million
Q1 2023 Apr 17, 2023	SELL	$144.61 - $166.54 $103,396 - $119,076	-715 Reduced 5.56%	12,155 $1.94 Million
Q4 2022 Feb 14, 2023	SELL	$138.31 - $165.87 $18,948 - $22,724	-137 Reduced 1.05%	12,870 $2.08 Million
Q4 2022 Jan 17, 2023	SELL	$138.31 - $165.87 $138,724 - $166,367	-1,003 Reduced 7.16%	13,007 $2.1 Million
Q3 2022 Oct 14, 2022	BUY	$134.21 - $153.93 $54,086 - $62,033	403 Added 2.96%	14,010 $1.88 Million
Q2 2022 Jul 18, 2022	SELL	$137.62 - $174.96 $10,871 - $13,821	-79 Reduced 0.58%	13,607 $2.08 Million
Q1 2022 Apr 25, 2022	SELL	$131.98 - $163.75 $28,507 - $35,370	-216 Reduced 1.55%	13,686 $2.22 Million
Q4 2021 Jan 25, 2022	BUY	$107.43 - $135.93 $37,493 - $47,439	349 Added 2.58%	13,902 $1.88 Million
Q3 2021 Oct 21, 2021	SELL	$106.4 - $120.78 $9,363 - $10,628	-88 Reduced 0.65%	13,553 $1.46 Million
Q2 2021 Jul 19, 2021	BUY	$105.21 - $117.21 $194,848 - $217,072	1,852 Added 15.71%	13,641 $1.54 Million
Q1 2021 Apr 19, 2021	BUY	$102.3 - $112.62 $66,597 - $73,315	651 Added 5.84%	11,789 $1.28 Million
Q4 2020 Jan 14, 2021	BUY	$80.49 - $108.67 $54,169 - $73,134	673 Added 6.43%	11,138 $1.19 Million
Q3 2020 Oct 19, 2020	SELL	$85.91 - $100.83 $53,436 - $62,716	-622 Reduced 5.61%	10,465 $917,000
Q2 2020 Jul 28, 2020	SELL	$73.37 - $98.18 $24,945 - $33,381	-340 Reduced 2.98%	11,087 $1.09 Million
Q1 2020 Apr 20, 2020	SELL	$64.5 - $97.79 $85,398 - $129,473	-1,324 Reduced 10.38%	11,427 $871,000
Q4 2019 Jan 27, 2020	SELL	$72.13 - $90.25 $34,983 - $43,771	-485 Reduced 3.66%	12,751 $1.13 Million
Q3 2019 Oct 16, 2019	SELL	$62.98 - $75.72 $41,692 - $50,126	-662 Reduced 4.76%	13,236 $1 Million
Q2 2019 Jul 08, 2019	SELL	$65.7 - $83.98 $147,825 - $188,955	-2,250 Reduced 13.93%	13,898 $1.01 Million
Q1 2019 Apr 23, 2019	SELL	$77.14 - $90.79 $1,388 - $1,634	-18 Reduced 0.11%	16,148 $1.3 Million
Q4 2018 Jan 17, 2019	SELL	$77.85 - $96.01 $23,355 - $28,803	-300 Reduced 1.82%	16,166 $1.49 Million
Q3 2018 Oct 09, 2018	BUY	$88.91 - $98.84 $51,034 - $56,734	574 Added 3.61%	16,466 $1.56 Million
Q2 2018 Jul 23, 2018	SELL	$89.78 - $106.23 $48,391 - $57,257	-539 Reduced 3.28%	15,892 $1.47 Million
Q1 2018 Apr 23, 2018	SELL	$92.01 - $123.21 $80,508 - $107,808	-875 Reduced 5.06%	16,431 $1.56 Million
Q4 2017 Jan 24, 2018	BUY	$89.56 - $98.21 $38,152 - $41,837	426 Added 2.52%	17,306 $1.67 Million
Q3 2017 Oct 19, 2017	BUY	$69.85 - $89.22 $1.18 Million - $1.51 Million	16,880	16,880 $1.5 Million

Others Institutions Holding ABBV

# of Institutions

3,852

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $310B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Douglas Lane & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Douglas Lane & Associates, LLC with notifications on news.

Account

Douglas Lane & Associates, LLC Abb Vie Inc. Transaction History